dbl™ ephedrine sulfate
pfizer new zealand limited - ephedrine sulfate 30 mg/ml - solution for injection - 30 mg/ml - active: ephedrine sulfate 30 mg/ml excipient: sodium chloride water for injection
dbl ephedrine sulfate 30mg/1ml injection
pfizer australia pty ltd - ephedrine sulfate, quantity: 30 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - ephedrine is indicated in the treatment of shock unresponsive to fluid replacement. it is also indicated in the treatment of hypotension secondary to spinal anaesthesia. ephedrine sulfate injection has also been used in the treatment of bronchial asthma and reversible bronchospasm although more selective agents (beta adrenergic agonists) are now available.
ephedrine hydrochloride sxp ephedrine hydrochloride 30mg / ml solution for injection ampoule
southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.
ephedrine sulfate injection, solution
par pharmaceutical, inc. - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none r isk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations] . animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. c linical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. th
ephedrine sulfate injection, solution
nexus pharmaceuticals inc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml - ephedrine sulfate injectionn, usp is indicated in the treatment of allergic disorders, such as bronchial asthma the drug has long been used as a pressor agent, particularly during spinal anesthesia when hypotensionn frequently ooccurs. in stokes-adams syndromeme with complete heart block, ephedrine has a value similar to that of epinephrine. it is indicated as a central nervous system stimulant in narcolepsy and depressive states. it is also used in myasthenia gravis. allergic reactions to ephedrine sulfate are rare. the hypersensitivity, if known, is a specific contraindication. patients hypersensitive to other sympathomimetics may also be hypersensitive to ephedrine sulfate. prolonged abuse of ephedrine sulfate injection, usp can lead to symptoms of paranoid schizophrenia. when this occurs, patients exhibit such physical signs as tachycardia, poor nutrition and hygiene, fever, cold sweat and dilated pupils. some measure of tolerance may develop with prolonged or excessive use but addiction does not occur. t
ephedrine sulfate injection
akorn - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml - ephedrine sulfate injection, usp is indicated in the treatment of allergic disorders, such as bronchial asthma the drug has long been used as a pressor agent, particularly during spinal anesthesia when hypotension frequently occurs. in stokes-adams syndrome with complete heart block, ephedrine has a value similar to that of epinephrine. it is indicated as a central nervous system stimulant in narcolepsy and depressive states. it is also used in myasthenia gravis. allergic reactions to ephedrine sulfate are rare. the hypersensitivity, if known, is a specific contraindication. patients hypersensitive to other sympathomimetics may also be hypersensitive to ephedrine sulfate. prolonged abuse of ephedrine sulfate injection, usp can lead to symptoms of paranoid schizophrenia. when this occurs, patients exhibit such physical signs as tachycardia, poor nutrition and hygiene, fever, cold sweat and dilated pupils. some measure of tolerance may develop with prolonged or excessive use but addiction does not occur. tempor
ephedrine sulfate injection
sandoz inc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are clinical considerations due to underlying conditions (see clinical considerations ). in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively [see data ]. the estimated
dbl ephedrine sulfate injection 30 mgml
pfizer private limited - ephedrine sulfate - injection - 30 mg/ml - ephedrine sulfate 30 mg/ml
ephedrine sulfate injection
akorn - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations ]. animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. these
ephedrine sulfate injection, solution
par pharmaceutical, inc. - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none r isk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations] . animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. c linical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. th